Conshohocken, Pennsylvania-based Cencora (NYSE: COR) and Kite, a Gilead Sciences (Nasdaq: GILD) company, announced a distribution agreement covering two US FDA-approved CAR T-cell therapies, with Cencora providing specialty logistics and supply chain infrastructure to support Kite’s expanding authorized treatment center network across the US, including health systems and community oncology practices. Financial terms were not disclosed.
The agreement covers axicabtagene ciloleucel (Yescarta) and brexucabtagene autoleucel (Tecartus), both autologous CAR T-cell therapies already approved by the US FDA for hematologic malignancies. Cencora will provide services through its cell and gene therapy service line, including order management and cold chain distribution support, as Kite broadens its footprint beyond established academic centers into community-based oncology settings.
The deal is scoped exclusively to the US market. No exclusivity terms, per-unit fee structures, or volume thresholds were disclosed in the announcement, and no equity or milestone components were referenced, consistent with a commercial services arrangement rather than a financial transaction.
Kite has been an active collaborator on next-generation CAR T development alongside its commercial portfolio. In a separate transaction, Kite and Santa Monica, California-based Arcellx (Nasdaq: ACLX) are jointly advancing anito-cel (anitocabtagene autoleucel), a BCMA-targeting CAR T candidate for relapsed or refractory multiple myeloma, under a collaboration valued at potentially more than USD 4 billion, with Kite holding ex-US commercialization rights.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/